ArticleEndocrine connections2026
Exploring causal associations between the plasma proteome and bone mineral density: a Mendelian randomization study.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteoporosis is characterized by reduced bone mineral density (BMD) and an increased risk of fractures, but the relationships between plasma proteins and site-specific BMD phenotypes remain unclear. We aimed to investigate the potential causal associations of plasma proteins with BMD using a Mendelian randomization (MR) analysis.
methodsWe conducted a two-sample MR analysis as the primary analysis, using cis-protein quantitative trait locus (pQTL) instruments from nine proteomic genome-wide association studies and summary statistics for total-body, forearm, femoral-neck, and lumbar-spine BMD. Prioritized associations were evaluated using colocalization, Steiger directionality testing, protein-altering variant (PAV) annotation, cis-expression quantitative trait locus (cis-eQTL) overlap, and targeted replication. Protein-protein interaction (PPI), pathway enrichment, and druggability analyses were exploratory.
resultsTwenty-three study-specific associations met the significance thresholds and involved 12 proteins: F2, TGFBI, PLEKHA1, HTRA1, PKDCC, CFHR4, LRP4, RSPO3, DKK1, TNFRSF11A, SPP1, and IBSP. Strong colocalization supported associations of F2 with total-body BMD, TGFBI with femoral-neck BMD, and PLEKHA1 with total-body and lumbar-spine BMD. Steiger testing supported directionality for 22 of 23 associations, except PKDCC-forearm BMD. Targeted replication provided no statistically significant, directionally concordant support. LRP4 relied on the only direct target-protein PAV, while eight cis-pQTLs for six proteins overlapped with cis-eQTLs. Exploratory analyses implicated skeletal and extracellular matrix processes and targets of prior pharmacological interest.
conclusionUsing cis-pQTL-based MR, we identified circulating proteins associated with BMD phenotypes. Strong colocalization was observed for F2, TGFBI, and PLEKHA1, whereas the remaining associations require additional validation. These findings provide genetic support for established bone-related pathways and highlight candidate proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.